Article Text

other Versions

Download PDFPDF
Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers
  1. Joan Isabelle Tankou1,
  2. Olivia Foley2,3,
  3. Michele Falzone2,
  4. Rajeshwari Kalyanaraman4 and
  5. Kevin M Elias2,3,5
  1. 1Department of Obstetrics and Gynecology, Gynecologic Oncology, Washington University in St Louis, St Louis, Missouri, USA
  2. 2Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts, USA
  3. 3Harvard Medical School, Boston, Massachusetts, USA
  4. 4Department of Obstetrics and Gynecology, St Francis Hospital, Hartford, Connecticut, USA
  5. 5Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  1. Correspondence to Dr. Kevin M Elias, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA 02115, United States; kelias{at}bwh.harvard.edu

Abstract

Objective The objective of this study was to determine whether the implementation of an enhanced recovery after surgery (ERAS) protocol is associated with earlier return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers.

Methods Participants comprised consecutive patients (n=278) with a preoperative diagnosis of stage IIIC or IV ovarian cancer, divided into those that received treatment before versus after implementation of an ERAS protocol at our institution. All patients received at least three cycles of neoadjuvant chemotherapy with a platinum based regimen and underwent interval cytoreduction via laparotomy with the intent to deliver additional cycles of chemotherapy postoperatively. The primary outcome was defined as the timely return to intended oncologic treatment, defined as the percentage of patients initiating adjuvant chemotherapy within 28 days postoperatively.

Results The study cohorts included 150 pre-ERAS patients and 128 post-ERAS patients. Median age was 65 years (range 58–71). Most patients (211; 75.9%) had an American Society of Anesthesiologists score of 3, and the median operative time was 174 min (range 137–219). Median length of stay was 4 days (range 3–5 days) in the pre-ERAS cohort versus 3 days (range 3–4) in the post-ERAS cohort (p<0.0001). At 28 days after operation, 80% of patients had resumed chemotherapy in the post-ERAS cohort compared with 64% in the pre-ERAS cohort (odds ratio (OR) 2.29, 95% confidence interval (CI) 1.36 to 3.84; p=0.002). In multivariate logistic regression analysis, the ERAS protocol was the strongest predictor of timely return to intended oncology treatment (OR 10.18, 95% CI 5.35 to 20.32).

Conclusion An ERAS protocol for gynecologic oncology patients undergoing interval cytoreductive surgery is associated with earlier resumption of adjuvant chemotherapy.

  • gynecologic surgical procedures
  • postoperative period
  • preoperative Care
  • ovarian neoplasms
  • surgical procedures
  • operative

Data availability statement

All data relevant to the study are included in the article or uploaded as supplemental information.

Statistics from Altmetric.com

Data availability statement

All data relevant to the study are included in the article or uploaded as supplemental information.

View Full Text

Footnotes

  • Twitter @kevin_elias

  • Contributors JIT led the study, primarily led the conceptualization, data curation, and formal analysis of the study, wrote the original draft of the manuscript, and reviewed, edited, and approved the final version of the manuscript. OF collected data for the study and contributed to the drafting, review, and editing of the manuscript. MF and RK assisted in data collection and analysis. KE supervised the conceputalization, design, statistical analysis, and writing of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.